Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22984
Title: Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.
Authors: La Joie, Renaud;Ayakta, Nagehan;Seeley, William W;Borys, Ewa;Boxer, Adam L;DeCarli, Charles;Doré, Vincent;Grinberg, Lea T;Huang, Eric;Hwang, Ji-Hye;Ikonomovic, Milos D;Jack, Clifford;Jagust, William J;Jin, Lee-Way;Klunk, William E;Kofler, Julia;Lesman-Segev, Orit H;Lockhart, Samuel N;Lowe, Val J;Masters, Colin L;Mathis, Chester A;McLean, Catriona L;Miller, Bruce L;Mungas, Daniel;O'Neil, James P;Olichney, John M;Parisi, Joseph E;Petersen, Ronald C;Rosen, Howard J;Rowe, Christopher C;Spina, Salvatore;Vemuri, Prashanthi;Villemagne, Victor L;Murray, Melissa E;Rabinovici, Gil D
Affiliation: Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA.
Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, Victoria, Australia
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Department of Anatomical Pathology, Alfred Hospital, Melbourne, Australia
The Florey Institute, The University of Melbourne, Melbourne, Victoria, Australia
Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA
Department of Neurology, University of Pittsburgh, PA, USA
Department of Psychiatry, University of Pittsburgh, PA, USA
Alzheimer's Disease Research Center, University of Pittsburgh, PA, USA
Department of Internal Medicine, Division of Gerontology and Geriatric Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA
Biomedical Isotope Facility, MBIB Division, Lawrence Berkeley National Laboratory, CA, USA
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
Department of Pathology, Stritch School of Medicine, Loyola University, Maywood, IL, USA
Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
Department of Neurology, University of California, Davis, CA, USA
Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
Department of Radiology, Mayo Clinic, Rochester, MN, USA
Helen Wills Neuroscience Institute, University of California Berkeley, CA, USA
Alzheimer's Disease Center, Department of Pathology, University of California Davis, CA, USA
Department of Pathology, University of Pittsburgh, Pennsylvania, USA
Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
Department of Nuclear Medicine, Mayo Clinic, Rochester, MN, USA
Department of Radiology, University of Pittsburgh, PA, USA
Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
Department of Neurology, University of California, Davis, CA, USA
Department of Neurology, Mayo Clinic, Rochester, MN, USA
Memory & Aging Center, Department of Neurology, University of California, San Francisco, CA, USA
Department of Radiology, Mayo Clinic, Rochester, MN, USA
Department of Neuroscience, Mayo Clinic, Jacksonville, FL, USA
Issue Date: 15-Feb-2019
EDate: 2018-10-19
Citation: Alzheimer's & dementia : the journal of the Alzheimer's Association 2019; 15(2): 205-216
Abstract: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [11C]PIB-positron emission tomography ([11C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification. Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings. CL values increased with each CERAD neuritic plaque score increment (median -3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). Our study demonstrated the robustness of a multisite Centiloid [11C]PIB-PET study and established a range of pathology-based CL thresholds.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22984
DOI: 10.1016/j.jalz.2018.09.001
ORCID: 0000-0002-8051-0558
0000-0002-5832-9875
PubMed URL: 30347188
Type: Journal Article
Multicenter Study
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Subjects: Alzheimer's disease neuropathologic changes
CERAD
Centiloid
Harmonization
Neuropathology
Pittsburgh compound-B
Positron emission tomography
Thal
Threshold
β-amyloid
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.